A carregar...
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO...
Na minha lista:
| Publicado no: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7790525/ https://ncbi.nlm.nih.gov/pubmed/33457091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1746172 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|